Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas [Phase 1]
This document reports the status of a Phase 1 clinical trial evaluating GLB-002 in patients with relapsed or refractory Non-Hodgkin Lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of intratumoral mRNA-2752 in advanced malignancies has completed, with expansion cohorts in seve…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL [EARLY_Phase 1]
An early-phase trial evaluating the safety and feasibility of CD19 CAR T cells manufactured with the CliniMACS Prodigy platform for relapsed…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies [Phase 1, Phase 2]
Clinical trial update on CLIC-1901 for relapsed/refractory CD19-positive hematologic malignancies (Phase 1/Phase 2), currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-13Clinical Trial Update: Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG [NA]
A clinical trial investigating early detection of anthracycline cardiotoxicity risk in lymphoma patients using TEP/CT-FDG imaging, currently…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 2]
Phase 2 study of TAK-007 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma has posted results and remains active but not rec…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [Phase 2]
This clinical trial update describes a Phase 2 study evaluating TCRγδ T cells and memory T cells with selective use of blinatumomab as part …
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial of DZD8586 in relapsed or refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion [Phase 2]
A Phase 2 clinical trial evaluating allogeneic stem cell transplantation with alpha/beta T cell and CD19+ B cell depletion for malignant and…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab plus ICE chemotherapy for refractory or recurrent CD20-positive mature non-Hodgkin lymphoma i…
-
CLINICAL_TRIALS withdrawal · 2025-08-08Clinical Trial Update: Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
The HY004 cell injection trial for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdrawn.
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
An update on an ongoing Phase 1/2 clinical trial evaluating Estrella Biopharma's EB103 T-cell therapy in adults with relapsed/refractory B-c…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating allogeneic CD19-targeting CAR-γδT cells for relapsed/refractory Non-Hodgkin lymphoma is currently recr…
-
EMA approval · 2025-08-05EMA Authorised: Riximyo (rituximab) — Sandoz GmbH
EMA authorized the biosimilar Riximyo (rituximab) by Sandoz GmbH for multiple indications, including Non-Hodgkin lymphoma, rheumatoid arthri…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [Phase 3]
This document reports the completion of a Phase 3 trial comparing JCAR017 to standard of care in adults with high-risk, transplant-eligible …
-
CLINICAL_TRIALS trial_result · 2025-08-01Clinical Trial Update: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) [Phase 1]
The ASPEN-01 Phase 1 trial of Evorpacept (ALX148) in patients with advanced solid tumors and Non-Hodgkin lymphoma has completed its Phase 1 …
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL [Phase 1, Phase 2]
A Phase 1/2 study of an allogeneic CD19-targeting CAR-γδT cell therapy (QH103E) for relapsed/refractory non-Hodgkin lymphoma is currently re…
-
CLINICAL_TRIALS research · 2025-07-28Clinical Trial Update: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies [Phase 1, Phase 2]
This document outlines a Phase I/II clinical trial of ALETA-001 for various B-cell lymphomas, with recruitment ongoing and sponsored by Canc…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) [Phase 1]
Phase 1 clinical trial of CD30-directed CAR T cells for relapsed CD30-expressing Hodgkin lymphoma and non-Hodgkin lymphoma is currently recr…
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: Living Conditions After Non-Hodgkin's Lymphoma in France
A completed clinical trial in France, sponsored by Centre Hospitalier Universitaire Dijon, evaluating living conditions after Non-Hodgkin ly…
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Haplo Peripheral Blood Sct In GVHD Prevention [Phase 1]
Phase 1 trial update reporting the completion of a haploidentical peripheral blood stem cell transplantation approach for the prevention of …
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Administration of Donor T Cells With the Caspase-9 Suicide Gene [Phase 1]
A Phase 1 trial evaluating donor T cells engineered with a caspase-9 suicide gene to enable controlled safety in hematologic diseases.
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene [Phase 1]
Phase 1 clinical trial of CASPALLO allodepleted T cells engineered with an inducible caspase-9 suicide gene; the study is currently active b…
-
EMA approval · 2025-07-09EMA Authorised: Ituxredi (rituximab) — Reddy Holding GmbH
The EMA authorised Ituxredi (rituximab) by Reddy Holding GmbH. It is indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and r…